Interestingly they got a $1.4 mill increase ASR in the June quarter, but only $1 mill increase in September quarter with no explanation as to why the slow down in growth. I am curious?
OAR Chris Judd's Talk Ya Book: Orthocell building on 'enormous potential' with steady growth - and US push to come
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game